Comerica Bank Has $92.14 Million Stake in Abbott Laboratories $ABT

Key Points

• Comerica Bank trimmed its position in Abbott by 3.9%, selling 29,650 shares and leaving it with 735,393 shares valued at about $92.14 million per its SEC filing.
• Abbott slightly beat quarterly estimates (EPS $1.15 vs. $1.14; revenue $11.16B vs. $10.99B), set FY‑2026 guidance of $5.38–$5.58 EPS and announced a $0.63 quarterly dividend (2.8% yield).
• Several brokerages have lowered price targets recently, but the consensus rating remains a Moderate Buy with an average price target of $119.43.

Comerica Bank trimmed its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 735,393 shares of the healthcare product maker's stock after selling 29,650 shares during the period. Comerica Bank's holdings in Abbott Laboratories were worth $92,137,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock valued at $648,000 after buying an additional 162 shares during the last quarter. United Bank increased its stake in Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC increased its stake in Abbott Laboratories by 13.6% in the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after buying an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock valued at $195,267,000 after buying an additional 292,547 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Eric Shroff sold 709 shares of the company's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 over the last ninety days. Company insiders own 0.46% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on ABT. UBS Group lowered their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Citigroup lowered their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating on the stock in a research note on Friday, April 17th. Evercore lowered their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Freedom Capital upgraded shares of Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 29th. Finally, Royal Bank Of Canada lowered their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $119.43.

Abbott Laboratories Stock Up 0.0%

Abbott Laboratories stock opened at $91.16 on Monday. The firm has a market capitalization of $158.76 billion, a PE ratio of 25.53, a P/E/G ratio of 1.52 and a beta of 0.79. The company's 50-day moving average is $105.96 and its 200-day moving average is $117.11. Abbott Laboratories has a fifty-two week low of $90.72 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. Abbott Laboratories's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories's payout ratio is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.